Core Viewpoint - ICON plc is under investigation for potential securities law violations following a significant drop in its stock price due to concerns over accounting practices and internal controls [2][4]. Group 1: Company Investigation - Shares of ICON plc fell over 30% in premarket trading on February 12, 2026, after the company disclosed that its Audit Committee is investigating certain accounting practices and internal controls, particularly regarding revenue recognition from 2023 through 2025 [2]. - ICON expects to report material weaknesses in internal control over financial reporting, has delayed the release of its Q4 and FY25 financial results, and has withdrawn its previously issued 2025 guidance [2]. Group 2: Legal Actions and Investor Support - Block & Leviton is investigating whether ICON plc committed securities law violations and may file an action to recover losses on behalf of investors [4]. - Investors who have lost money in their ICON plc investment are encouraged to contact Block & Leviton to learn more about potential recovery options [3][5].

Core Points - A class action lawsuit has been filed against CoreWeave, Inc. and certain senior executives for securities fraud following significant stock drops due to potential violations of federal securities laws [1][3] - Investors are encouraged to seek additional information regarding the lawsuit and their legal options [2][9] Company Overview - CoreWeave is an AI-focused cloud computing company that operates data centers providing high-performance GPU infrastructure [4] - The company relies on partnerships, including a merger agreement with Core Scientific announced on July 7, 2025 [4] Allegations and Stock Performance - CoreWeave allegedly overstated its ability to meet customer demand and concealed significant construction delays at its data centers [5] - On October 30, 2025, CoreWeave's stock dropped by $8.87 per share (over 6%) after the merger with Core Scientific was terminated due to insufficient shareholder votes [6] - Following a revenue guidance reduction on November 10, 2025, the stock fell by $17.22 per share (over 16%) due to delays from a third-party data center developer [7] - A report on December 15, 2025, indicated further delays in a major data center project, causing an additional drop of $2.85 per share (over 3%) [8]

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock price drops linked to alleged violations of federal securities laws [1][3]. Company Overview - Fermi Inc. is an energy and AI infrastructure company focused on building large-scale nuclear reactors to support grid-independent data centers for AI workloads [4]. - The company's flagship project is Project Matador, designed to provide dedicated power for AI operations [4]. IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Stock Price Impact - On December 12, 2025, Fermi's stock dropped by $5.16 per share, over 33%, following the announcement that the First Tenant was terminating its agreement [7]. - The stock price fell from $15.25 per share on December 11, 2025, to $10.09 per share on December 12, 2025 [7]. Legal Proceedings - Investors have until March 6, 2026, to seek appointment as lead plaintiffs in the case, which is pending in the U.S. District Court for the Southern District of New York [3]. - The lawsuit includes claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Sections 11 and 15 of the Securities Act of 1933 [3]. Legal Representation - Bleichmar Fonti & Auld LLP is representing the plaintiffs in this class action and has a history of successful recoveries in similar cases [9].

Core Viewpoint - Kirby McInerney LLP is investigating potential securities fraud claims against KDDI Corporation, focusing on possible violations of federal securities laws by the company and its senior management [1] Group 1: Investigation Details - The investigation was prompted by KDDI's announcement on February 6, 2026, regarding the postponement of its earnings report for the third quarter of the fiscal year ending March 2026, citing uncertainties related to quarterly results and an internal investigation [1] - Following the announcement, KDDI's share price fell by $2.03, or approximately 11.44%, from $17.74 on February 5, 2026, to close at $15.71 on February 6, 2026 [1] Group 2: Legal Context - No lawsuit has been filed yet, and the investigation is ongoing to determine if claims can be brought under federal securities laws [1] - Investors who purchased or acquired KDDI securities are encouraged to contact Kirby McInerney LLP for more information regarding their rights or interests related to the investigation [1]

Core Viewpoint - Block & Leviton is investigating Carvana Co. for potential securities law violations following a report alleging that the company's profitability is based on undisclosed related-party transactions [1][2][4] Group 1: Investigation Details - Carvana's shares fell over 20% on January 28 after Gotham City Research reported that the company's earnings were subsidized by related-party transactions with DriveTime and Bridgecrest [2] - The report claims that DriveTime incurred over $1 billion in cash losses while leveraging up to 20x to 40x EBITDA to support Carvana's earnings [2] - Bridgecrest reportedly marked down billions in loans as Carvana recognized gains on loan sales [2] Group 2: Eligibility and Actions - Investors who purchased Carvana common stock and experienced a decline in share value may be eligible to recover losses, regardless of whether they sold their investment [3] - Block & Leviton is prepared to file actions to recover losses on behalf of affected investors [4] Group 3: Whistleblower Information - Individuals with non-public information about Carvana are encouraged to assist in the investigation or report to the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]

Core Insights - Coty Inc. reported a quarterly loss of $126.9 million, which is a significant outlier in the beauty and personal care sector, where competitors like Estée Lauder, L'Oréal, and Shiseido have shown stable or improving margins [2] - The company's like-for-like revenue declined approximately 3%, contrasting with previous guidance of low-single-digit growth, and the earnings per share (EPS) missed consensus estimates by 22%, indicating a substantial gap between public expectations and internal performance [2][3] - Coty has withdrawn its full-year FY 2026 guidance and introduced a new turnaround strategy called "Coty. Curated." under interim CEO Markus Strobel, which aims to refocus on core brands [3] Company Performance - The reported loss of $126.9 million places Coty among the widest negative earnings surprises in the mid-cap consumer space for the reporting period [2] - Prior to the earnings announcement, management had expressed optimism about the second quarter, expecting to be at the "more favorable end of our guidance range," which contrasts sharply with the actual reported loss [4] Strategic Changes - The introduction of the "Coty. Curated." strategy coincided with the withdrawal of forward-looking targets, leading to a negative reaction from investors and analysts [3]

Deadline Approaching: Picard Medical, Inc. (PMI) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. SmithFeb 11, 2026 1:04 PM Eastern Standard Time# Deadline Approaching: Picard Medical, Inc. (PMI) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. SmithShare-- -BENSALEM, Pa.--([BUSINESS WIRE])--Law Offices of Howard G. Smith reminds investors of the upcoming April 3, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Pi ...

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock price drop attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as claims under Sections 11 and 15 of the Securities Act of 1933 [3]. - Investors have until March 6, 2026, to request to lead the case in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - Fermi Inc. is an energy and AI infrastructure company aiming to build large-scale nuclear reactors to support grid-independent data centers for AI companies [4]. - The company's flagship project, Project Matador, is designed to provide dedicated power for AI workloads [4]. Group 3: IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Group 4: Stock Price Impact - Following the announcement of the First Tenant's termination of the construction agreement on December 11, 2025, Fermi's stock dropped by $5.16, or over 33%, from $15.25 to $10.09 per share [7].

Core Points - A class action lawsuit is pending against CoreWeave, Inc. (NASDAQ: CRWV) for allegedly misleading investors about its AI infrastructure scalability and revenue guidance [1][3] - The lawsuit claims that CoreWeave overstated its capacity to meet customer demand and downplayed operational risks related to reliance on a single third-party data center supplier [2][6] - Following delays at a critical data center in Denton, Texas, CoreWeave's market capitalization fell by approximately $14 billion, indicating significant investor losses [2][6] Allegations - The complaint alleges that CoreWeave concealed significant delays at its Denton facility, contradicting management's claims of "rapid scaling" [6] - It is claimed that the company's ability to recognize revenue from its multibillion-dollar backlog was dependent on infrastructure that was not on track for timely completion [6] - The stock experienced a 16% drop on November 11 after the company lowered its guidance, contributing to the overall decline in shareholder value [6] Legal Actions - Hagens Berman is actively advising investors who purchased CRWV shares during the class period from March 28, 2025, to December 15, 2025, and suffered losses [4] - The deadline for lead plaintiffs to submit their claims is March 13, 2026 [5] - Whistleblowers with non-public information regarding CoreWeave are encouraged to participate in the investigation or utilize the SEC Whistleblower program [5]

Core Viewpoint - Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against uniQure N.V. on behalf of investors who purchased shares between September 24, 2025, and October 31, 2025, alleging that the company made materially false and misleading statements regarding its drug AMT-130 and its regulatory approval process [1][2]. Group 1: Lawsuit Details - The lawsuit is titled Scocco v. uniQure N.V., filed in the U.S. District Court for the Southern District of New York [1]. - Investors can move to serve as lead plaintiff by April 13, 2026, and the firm encourages those affected to contact them for more information [2]. Group 2: Company Background - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, particularly Huntington's disease (HD) [1]. - The leading drug candidate, AMT-130, aims to slow the progression of HD, a fatal genetic disorder with no current cure [1]. Group 3: Clinical Trials and FDA Interaction - uniQure completed patient enrollment for two ongoing Phase I/II clinical trials for AMT-130 in March 2022 [1]. - The FDA had previously agreed that the Pivotal Study results could be compared to an external historical dataset (Enroll-HD) for the basis of a Biologics License Application (BLA) submission [1]. Group 4: Stock Performance and Offering - Following the announcement of positive topline results from the Pivotal Study on September 24, 2025, uniQure's stock price surged nearly 250%, from $13.66 to $47.50 per share [1]. - The company subsequently offered over 5.7 million shares and generated approximately $345 million in proceeds, despite uncertainties regarding AMT-130's future [2]. Group 5: Allegations of Misrepresentation - The complaint alleges that uniQure misrepresented the FDA's approval of the Pivotal Study design and downplayed the likelihood of delays in the BLA timeline [2]. - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the Pivotal Study data would suffice for a BLA submission, leading to a stock price drop of over 49% [2].